VIDEO: Biologics in IBD patients may reduce osteoporosis, bone fractures

ByMiguel Regueiro, MD

In this video exclusive, Miguel Regueiro, MD, discussed a presentation from Digestive Disease Week on the impact of biologics on the prevalence of osteoporosis and bone fractures in patients with inflammatory bowel disease.

Regueiro, chair of the department of gastroenterology, hepatology and nutrition at Cleveland Clinic, said they found patients with IBD treated with biologics were less likely to have osteoporosis and bone fractures compared with those not on biologics.

Biologics may decrease the inflammation and cytokines, therefore improve bone health and reduce bone fractures, according to Regueiro.

Published by:

Sources/Disclosures

Collapse

Source:

Eltelbany A. Abstract 612. Presented at: Digestive Disease Week; May 21-24, 2021 (virtual meeting).

Disclosures: Regueiro reports receiving research support from AbbVie, Janssen, Takeda and Pfizer; receiving unrestricted educational grants from AbbVie, Janssen, UCB, Pfizer, Takeda, Celgene, Genentech and Gilead; serving on the advisory board for and consultanting for AbbVie, Janssen, UCB, Takeda, Pfizer, Miraca Labs, Amgen, Celgene, Seres, Allergan, Genentech, Gilead, Salix, Prometheus, Lilly, TARGET Pharma Solutions and ALFASIGMA S.p.A.; receiving support from CME companies including CME Outfitters, Imedex, GI Health Foundation (GiHF), Cornerstones, Remedy, MJH Life Sciences; and receiving royalties from Wolters Kluwer Health as Author/Editor of UpToDate.

Digestive Disease Week

Read more

VIDEO: Biologics in IBD patients may reduce osteoporosis, bone fractures

Related Content